Shanxi Medical University   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Taiyuan China (1919)

Organization Overview

First Clinical Trial
2006
NCT00968929
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Fenyang Hospital Affiliated to Shanxi Medical University | First Hospital of Shanxi Medical University | Second Hospital of Shanxi Medical University | Shanxi Dayi Hospital | Shanxi Eye Hospital | Shanxi Medical University | Shanxi Province Cancer Hospital | Shanxi Provincial Maternity and Children's Hospital | Shanxi Provincial People's Hospital | Shanxi provincial peple's hospital | Shanxi Traditional Chinese Medical Hospital | Suping Wang | Taiyuan Central Hospital of Shanxi Medical University | The First Affiliated Hospital of Shanxi Medical University | The First Affiliated Hospital of Shanxi University of Traditional Chinese Medicine | The Tuberculosis Prevention and Treatment Hospital of Shanxi Province | Tumor Hospital of Shanxi Province

Active Ingredients

Drugs in Phase 4 Trials (46)

amfebutamone (1 trial)

amlodipine (norvasc) (2 trials)

andrographolide (1 trial)

azithromycin (zithromax) (1 trial)

budesonide (rhinocort) (2 trials)

cephalosporin (1 trial)

ciprofol (1 trial)

cisplatin (platinol) (5 trials)

clavulanate (Augmentin) (1 trial)

dexamethasone (1 trial)

dexmedetomidine (precedex) (1 trial)

doxycycline (vibramycin) (1 trial)

entecavir (baraclude) (3 trials)

ethambutol (myambutol) (1 trial)

etoposide (vepesid) (2 trials)

fluoroquinolone (1 trial)

fluoxetine (prozac) (2 trials)

fluvoxamine (luvox) (2 trials)

folic acid (2 trials)

gemcitabine (gemzar) (2 trials)

hepatitis b vaccine (recombinant) (recombivax) (8 trials)

interferon alpha-2b (Intron-A) (1 trial)

isoniazid (nydrazid) (1 trial)

ixazomib (ninlaro) (2 trials)

lenalidomide (revlimid) (2 trials)

levofloxacin (levaquin) (1 trial)

lithium (lithonate) (1 trial)

mesna (mesnex) (1 trial)

minocycline (minocin) (1 trial)

mirtazapine (remeron) (1 trial)

naltrexone (revia) (2 trials)

pegaspargase (oncaspar) (2 trials)

pomalidomide (pomalyst) (2 trials)

prednisone (meticorten) (2 trials)

procaine benzylpenicillin (novocaine) (1 trial)

propofol (diprivan) (4 trials)

pyrazinamide (Aldinamide) (1 trial)

qiliqiangxin (1 trial)

rifampin (1 trial)

sevoflurane (ultane) (2 trials)

shenyankangfu (1 trial)

streptokinase (streptase) (1 trial)

thymalfasin (zadaxin) (2 trials)

triptorelin (Trelstar) (1 trial)

urea (4 trials)

urokinase (kinlytic) (1 trial)

Drugs in Phase 3 Trials (19)

allopurinol (zyloprim) (1 trial)

capecitabine (xeloda) (2 trials)

carboplatin (paraplatin) (1 trial)

cladribine (leustatin) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

cytarabine (cytosar-u) (1 trial)

docetaxel (taxotere) (3 trials)

epirubicin (ellence) (1 trial)

febuxostat (uloric) (1 trial)

fluorouracil (efudex) (1 trial)

gelatin (1 trial)

lipiodol (1 trial)

neuregulin (1 trial)

paclitaxel (taxol) (3 trials)

pembrolizumab (keytruda) (1 trial)

rc48-adc (1 trial)

semustine (1 trial)

vinorelbine (navelbine) (1 trial)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (21)

apatinib (2 trials)

aripiprazole (abilify) (1 trial)

autologous cd19/cd22 chimeric antigen receptor t-cells (3 trials)

cytokine induced killer cells (1 trial)

doxorubicin (Doxil) (1 trial)

fruquintinib (1 trial)

gimeracil (1 trial)

gingko biloba (1 trial)

gulingji (1 trial)

ifosfamide (ifex) (1 trial)

neu2000kwl (1 trial)

olanzapine (zyprexa) (2 trials)

oteracil (1 trial)

quetiapine (seroquel) (1 trial)

Raltitrexed (1 trial)

risperidone (risperdal) (2 trials)

s-1 (1 trial)

somatropin (protropin) (1 trial)

tegafur (1 trial)

vincristine (oncovin) (1 trial)

ziprasidone (geodon) (2 trials)

Drugs in Other Trials (18)

atropine (1 trial)

avatrombopag (1 trial)

citalopram (celexa) (1 trial)

duloxetine (Cymbalta) (1 trial)

endostatin (endostar) (1 trial)

escitalopram (lexapro) (1 trial)

esketamine (spravato) (1 trial)

hetrombopag olamine (1 trial)

insulin human (humulin) (1 trial)

leflunomide (arava) (1 trial)

midazolam (versed) (1 trial)

paliperidone (invega) (1 trial)

paroxetine (paxil) (1 trial)

remifentanil (ultiva) (1 trial)

remimazolam (1 trial)

sertraline (zoloft) (2 trials)

sodium chloride (1 trial)

sufentanil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Cardiomyopathies (Phase 4)

Cardiomyopathy, Dilated (Phase 4)

Cerebral Infarction (Phase 2)

Cognitive Dysfunction (Phase 4)

Colorectal Neoplasms (Phase 2)

Delirium (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Disease (Phase 4)

Embolism (Phase 4)

Esophageal Squamous Cell Carcinoma (Phase 3)

Fibrosis (Phase 4)

Gout (Phase 3)

Heart Failure (Phase 3)

Heart Failure, Systolic (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hip Fractures (Phase 4)

Infarction (Phase 2)

Infertility (Phase 4)

Infertility, Female (Phase 4)

Kidney Diseases (Phase 4)

Liver Cirrhosis (Phase 4)

Lymphoma (Phase 4)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, T-Cell (Phase 4)

Multiple Myeloma (Phase 4)

Nasal Polyps (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms, Plasma Cell (Phase 4)

Neoplasms, Second Primary (Phase 2)

Pneumonia (Phase 4)

Postoperative Complications (Phase 4)

Pulmonary Embolism (Phase 4)

Purpura (Phase 4)

Purpura, Thrombocytopenic (Phase 4)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Schizophrenia (Phase 2)

Sinusitis (Phase 3)

Stroke (Phase 2)

Thrombocytopenia (Phase 2)

Thromboembolism (Phase 4)

Thrombosis (Phase 3)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial APIs: 104